Literature DB >> 29244096

Treatment of pulmonary tuberculosis: past and present.

Dmitry Borisovich Giller1, Boris Dmitrievich Giller1, Galina Vitalievna Giller1, Galina Vladimirovna Shcherbakova1, Anuar Bahtibaevich Bizhanov1, Inga Igorevna Enilenis1, Aleksey Aleksandrovich Glotov1.   

Abstract

OBJECTIVES: Surgical interventional has been key in the treatment of tuberculosis (TB) for a long time. Its importance diminished after the emergence of chemotherapy. However, the spread of rapid multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB has led us to return to surgery to treat TB. Today, every second patient in Russia with destructive TB has either MDR or XDR TB, which is the reason for the low efficacy of conservative treatment. In 2015, treatment with drugs resulted in clinical recovery in only 29.8% of new cases of destructive TB acid-fast bacilli (AFB)+.
METHODS: The author's data from 1999 to 2016 have been analysed. The author performed 5599 surgeries on patients with pulmonary TB aged from 1 to 87 years (mean age 34.6 years). The most common reasons for surgical treatment were fibrotic cavitary and cavitary pulmonary TB, tuberculoma with destruction, tuberculous pleural empyema, caseous pneumonia and intrathoracic lymph nodes. The strategy of early collapse therapy and the use of surgery to treat TB was proposed in the Penza region of Russia; the results were analysed to estimate the long-term outcomes of treatment.
RESULTS: In 5599 surgeries, the full clinical effect was achieved in 93% of operated patients with MDR TB, in 92.1% of those with XDR TB and in 98% of patients without MDR or XDR resistance. According to the data from the Penza region, 3 years after surgery, 93.9% (149 of 159 cases) of the operated patients exhibited clinical recovery.
CONCLUSIONS: Taking into account the data from the World Health Organization on the insufficient level of therapeutic success in the treatment of MDR and XDR pulmonary TB, surgical treatment is necessary in regions with a high frequency of drug-resistant cases.

Entities:  

Mesh:

Year:  2018        PMID: 29244096     DOI: 10.1093/ejcts/ezx447

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  5 in total

1.  Identification of a new series of benzothiazinone derivatives with excellent antitubercular activity and improved pharmacokinetic profiles.

Authors:  Lu Xiong; Chao Gao; Yao-Jie Shi; Xin Tao; Juan Rong; Kun-Lin Liu; Cui-Ting Peng; Ning-Yu Wang; Qian Lei; Yi-Wen Zhang; Luo-Ting Yu; Yu-Quan Wei
Journal:  RSC Adv       Date:  2018-03-21       Impact factor: 4.036

Review 2.  Tuberculosis: mother of thoracic surgery then and now, past and prospectives: a review.

Authors:  Tamas F Molnar
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

3.  Revisiting the evolution of tuberculosis therapy: historical reflections in the modern era.

Authors:  Ahmed A Kolkailah; Setri Fugar; Juan Rey-Mendoza; Tania Campagnoli; Sherene Fakhran
Journal:  Oxf Med Case Reports       Date:  2018-08-09

Review 4.  Managing severe tuberculosis and its sequelae: from intensive care to surgery and rehabilitation.

Authors:  Simon Tiberi; Marcela Muñoz Torrico; Ananna Rahman; Maria Krutikov; Dina Visca; Denise Rossato Silva; Heinke Kunst; Giovanni Battista Migliori
Journal:  J Bras Pneumol       Date:  2019-04-25       Impact factor: 2.624

5.  Video-assisted thoracoplasty in pulmonary tuberculosis: a retrospective study.

Authors:  Dmitry B Giller; Boris D Giller; Galina V Giller; Galina V Scherbakova; Vadim V Koroev; Oleg Sh Kesaev; Yakub G Imagozhev; Aleksey A Glotov
Journal:  J Thorac Dis       Date:  2020-03       Impact factor: 2.895

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.